Search
α-Methylacetylfentanyl
go.drugbank.com/drugs/DB01532ExperimentalIllicitα-Methylacetylfentanyl is an analog of fentanyl with opioid analgesic properties.
R411
go.drugbank.com/drugs/DB05468ExperimentalIt is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7. … R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation.
MDX-1379
go.drugbank.com/drugs/DB05329InvestigationalMDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.
Tezacitabine
go.drugbank.com/drugs/DB06433InvestigationalA synthetic purine nucleoside analogue with potential antineoplastic activity.
CR002
go.drugbank.com/drugs/DB05139InvestigationalCR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. … This is a novel therapeutic approach to treat kidney inflammation.
Synonyms: Human monoclonal antibody against platelet-derived growth factor Dbeta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 dia...
beta-Naphthoflavone
go.drugbank.com/drugs/DB06732ExperimentalIt may be a chemopreventive agent. … β-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs).
(+)-Mefloquine
go.drugbank.com/drugs/DB05636Investigational(+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to
Imgatuzumab
go.drugbank.com/drugs/DB14884InvestigationalImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With